Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion

Recruiting Observational Study
Lung Cancer Lymph Node Metastasis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
958 (estimated)
Sponsor
Luzerner Kantonsspital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Background: Lung cancer is the leading cause of cancer related death worldwide. More than 80% of all lung tumors are Non-Small Cell Lung Cancers (NSCLC). Lymph node staging has a prognostic value and is crucial to establish the optimal treatment strategy in individual patients. It remains unknown whether dissecting the intrapulmonary lymph nodes (stations 13 and 14) is necessary for accurate stagi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Anatomical resection for NSCLC \<3 cm (lobectomy, bilobectomy, segmentectomy) * Samples from the intrapulmonary stations 12, 13, and 14 lymph nodes * Resection of lymphnodes station 10 and 11 during hilar separation. * R0 resection Exclusion Criteria: * Prior or synchronous …
Contacts

Fabrizio Minervini, MD, PhD

+410412051111

fabriziominervini@hotmail.com

CONTACT